Calidi Biotherapeutics Secures Investment
Calidi Biotherapeutics, Inc., a San Diego, CA-based clinical stage Immuno-oncology Company at the forefront of cell-based oncolytic virus immunotherapies for cancer, raised a Series A funding round of undisclosed amount. Backers included Korean firms Won & Partners and Greentable Co., Ltd.
The company intends to use the funds to advance manufacturing in preparation for its preIND and IND filings.
“We are excited to grow Calidi Biotherapeutics and further our mission to bring lifesaving treatments to cancer patients.” Said.
Allan Camaisa, CEO of Calidi Biotherapeutics. “Dr. Lee and Lumebio have been instrumental in helping us close out our series A raise. This funding will allow us to continue advancing our manufacturing processes as we prepare our preIND and IND package for Supernova 1 (SNV1c), a tumor-selective vaccinia virus combined with allogeneic adipose-derived mesenchymal stem cells (AD-MSC). We are excited to advance this asset into the clinic to target multiple cancer types.”
Led by Allan Camaisa, CEO, Calidi Biotherapeutics is a clinical stage immunooncology company advancing advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Supernova 1 (SNV1c) is a tumor-selective vaccinia virus combined with allogeneic adipose-derived mesenchymal stem cells (AD-MSC), the company informed.
In addition, the team is developing a universal cell delivery system to house, protect, and potentiate any oncolytic viruses currently in development, which can potentially enhance efficacy and improve patient safety.